Sacubitril/valsartan shows benefit in heart failure with ejection fraction above 40%

Sacubitril/valsartan leads to greater reduction in plasma NT-proBNP levels compared to valsartan alone after stabilization for worsening heart failure in patients with an ejection fraction (EF) above 40%, according to late breaking science presented today at Heart Failure 2023, a scientific congress of the European Society of Cardiology (ESC), and published in the Journal of the American College of Cardiology.

source https://medicalxpress.com/news/2023-05-sacubitrilvalsartan-benefit-heart-failure-ejection.html